Transplantation and Cellular Therapy Meetings | Conference

Anakinra Fails to Reduce CRS, ICANS Associated With Liso-Cel in LBCL

February 13th 2025

Anakinra did not reduce cytokine release syndrome or immune effector cell–associated neurotoxicity in patients with large B-cell lymphoma receiving liso-cel.

NKTR-255 Plus Anti-CD19 CAR T-Cell Therapy Demonstrates Safety and Preliminary Efficacy in R/R LBCL

February 13th 2025

NKTR-255 combined with CD19-directed CAR T-cell therapy improved 6-month CR rates vs placebo in patients with relapsed/refractory large B-cell lymphoma.

Obe-Cel Is Associated With Improved Outcomes in R/R B-ALL With Low-Risk CAR-HT Scores

February 13th 2025

A high-risk CAR-HEMATOTOX score was associated with worse outcomes with obe-cel in relapsed/refractory B-ALL.

Later-Line Ruxolitinib Use Produces Ongoing Benefit in Real-World Patients With cGVHD

February 25th 2024

Real-world ruxolitinib use in chronic GVHD was primarily in the second- or third-line, lasted for a median of 8 months, and involved dose adjustments.

Orca-T Data With Survival, Tolerability Extends to Older Patients With Hematologic Cancers

February 24th 2024

Encouraging data with RFS, OS, and NRM for Orca-T was also matched in a population of patients with hematologic cancers aged 55 years and older.

Dr Ramdial on Gemcitabine/Clofarabine/Busulfan for Lymphoma Stem Cell Transplant

February 24th 2024

Jeremy L. Ramdial, MD, discusses the myeloablative conditioning regimen gemcitabine, clofarabine, and busulfan in patients with aggressive lymphomas.

Retrospective Analysis Shows Post-HCT Survival Benefits With Orca-T Vs PTCy in Hematologic Malignancies

February 24th 2024

In a retrospective analysis, Orca-T improved survival rates vs PTCy in patients with hematologic malignancies receiving myeloablative conditioning.

Dr Gomez Arteaga on an Investigation of Orca-T Vs PTCy-Based HCT in Acute Leukemia and MDS

February 24th 2024

Alexandra Gomez Arteaga, MD, discusses a retrospective study of Orca-T vs post-transplant cyclophosphamide in acute leukemia and MDS.

Dr Banerjee on Nivolumab Use After CAR T-Cell Therapy Progression in Myeloma and NHL

February 24th 2024

Rahul Banerjee, MD, FACP, discusses the use of nivolumab in multiple myeloma or non-Hodgkin lymphoma after progression following CAR T-cell therapy.

Dr Bertaina on T-allo10 Infusion in Young Patients With Hematologic Malignancies

February 24th 2024

Alice Bertaina MD, PhD, discusses T-allo10 infusion post–aβdepleted-HSCT in young patients with hematologic malignancies.

Belumosudil Plus Ruxolitinib Displays Activity in Steroid-Refractory/-Dependent cGVHD

February 23rd 2024

Belumosudil plus ruxolitinib elicited responses with acceptable tolerability in patients with chronic graft-vs-host disease.

Dr Auletta on the Impact of Post-Transplant Cyclophosphamide in Hematologic Malignancies

February 23rd 2024

Jeffery Auletta, MD, discusses the impact of post-transplant cyclophosphamide in hematologic malignancies.

Dr Hamilton on HRQOL Differences With Gilteritinib Vs Placebo in Post-Transplant FLT3-ITD+ AML

February 23rd 2024

Betty Hamilton, MD, discusses quality of life differences between post-transplant gilteritinib vs placebo in FLT3-ITD–positive acute myeloid leukemia.

Dr Lee on 3-Year Follow-Up Data From the ROCKstar Trial of Belumosudil in cGVHD

February 23rd 2024

Stephanie Lee, MD, MPH, discusses 3-year follow-up data from the phase 3 ROCKstar Study of belumosudil in cGVHD.

Immune Engager Therapies Demonstrate Promise Following Relapse on Ide-Cel in Multiple Myeloma

February 23rd 2024

Treatment with immune engager therapies following relapse on ide-cel resulted in better median PFS vs other therapies for patients with multiple myeloma.

Liso-Cel Demonstrates Durable Efficacy in Relapsed/Refractory CLL/SLL

February 23rd 2024

Lisocabtagene maraleucel elicited durable responses in patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

Concomitant Azoles Does Not Affect Clinical Outcomes With Ruxolitinib in Acute GVHD

February 23rd 2024

Concomitant azoles did not negatively affect efficacy with ruxolitinib or best available therapy in patients with acute graft-versus-host disease.

Cilta-Cel Sustains MRD-Negative Responses in Previously Treated Multiple Myeloma

February 23rd 2024

Cilta-cel continues to elicit deep and durable responses in patients with early relapsed multiple myeloma, including those refractory to lenalidomide.

Ruxolitinib Plus Belumosudil Boosts Responses in Chronic GVHD

February 23rd 2024

Ruxolitinib and belumosudil demonstrated a beneficial ORR, indicating synergistic effects in targeting multiple inflammatory pathways in chronic GVHD.

Ruxolitinib Cream Is Tolerable and Effective in Cutaneous GVHD

February 23rd 2024

A cream formulation of ruxolitinib was deemed safe and effective compared with placebo in patients with cutaneous graft-versus-host disease.

x